

FEB 01 2007


REMARKS

The Examiner has required restriction to one of four inventions under 35 U.S.C. §121.

In response to the Examiner's Restriction, applicants elect without traverse Group IV, claims 16-24, directed to a method of treating a patient or ex-vivo cell using the compounds of the present invention. This election is made without waiver of applicants' rights to pursue claims to the non-elected subject matter either in this application or in other applications claiming benefit herefrom.

The Examiner has further required an election under this Group IV of a single compound and a single disease or cell.


Applicants elect compound 2, disclosed in Example 2, page 30 of the specification as filed:



Per the Examiner's requirement of an election of a single disease or cell, applicants elect Alzheimer's disease.

Applicants request that the Examiner enter the above election, and allow the pending claims to pass to issue.

Respectfully submitted,

for  28, 981
Nandakumar Govindaswamy,
Reg. No. 56,285
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, MA 02139-4242
Tel.: (858) 404-5310
Fax.: (617) 444-6483
Customer No.: 27916